Rachel Legmann – VJRegenMed

Tangential Flow Depth Filtration in viral vector manufacturing

Simon Ng — Thu, 03 Mar 2022 17:46:23 +0000

Rachel Legmann, PhD, Repligen, Waltham, MA, discusses the Tangential Flow Depth Filtration (TFDF) platform and its benefits. TFDF combines tangential flow and depth filtration in a single closed system, enabling high cell density cultures for the production of various viral vectors such as adeno-associated viruses (AAV) and lentiviruses in gene therapies. A high cell density results in higher viral vector yields and a perfusion system allows the final product to be continuously collected. The platform additionally requires a lower surface area for defiltration, meaning that viral vectors can be manufactured in a shorter timeframe. This interview took place at Advanced Therapies Week 2022.

Meeting the increasing demand for viral vectors

Simon Ng — Fri, 18 Feb 2022 15:46:07 +0000

Rachel Legmann, PhD, Repligen, Waltham, MA, describes issues in producing viral vectors and approaches to improve manufacturing capabilities. Low yield and constraints in bioreactor capacity affects a wide range of viral vectors including adeno-associated viral (AAV) vectors, lentiviral vectors, and oncolytic vectors. Additional barriers include the process of replicating viral vectors, where transfection and lysis are stages in the manufacturing process that are difficult to scale up. Viral vectors are also more difficult to produce cost effectively due to the stricter safety regulations needed. This interview took place at Advanced Therapies Week 2022.

Strategies for large scale viral vector development

Simon Ng — Fri, 18 Feb 2022 15:46:05 +0000

Rachel Legmann, PhD, Repligen, Waltham, MA, gives her perspectives on how to successfully develop viral vectors, including the need to have scalable process ready for commercialization. Dr Legmann additionally emphasizes the importance of the product meeting existing regulatory guidelines, especially before mass manufacturing, as well as choosing a suitable platform that can flexibly switch between different modalities, as the formulation will only need to be altered in such circumstances. This interview took place at Advanced Therapies Week 2022.